Early impact of lenvatinib on liver function and its prognostic significance: a single-center retrospective study.
코호트
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
40 patients with advanced HCC who received ≥ 2 months of lenvatinib treatment from January 2020 to January 2024 and had at least one efficacy and safety assessment.
I · Intervention 중재 / 시술
≥ 2 months of lenvatinib treatment from January 2020 to January 2024 and had at least one efficacy and safety assessment
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] The baseline ALBI score serves as a key prognostic marker, highlighting the necessity for meticulous monitoring of hepatic function, particularly in patients with compromised baseline liver reserve. [LIMITATIONS] The limitations of this study include its retrospective design and the potential for selection bias arising from the requirement for at least 2 months of treatment.
[OBJECTIVE] Lenvatinib shows efficacy for tumor response and survival in patients with advanced hepatocellular carcinoma (HCC).
- p-value P < 0.05
- 95% CI 16.3-29.3
- 추적기간 18.5 months
- 연구 설계 cohort study
APA
Wang P, Liu S, Lu X (2026). Early impact of lenvatinib on liver function and its prognostic significance: a single-center retrospective study.. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, 31(2), 132-140. https://doi.org/10.1080/1354750X.2026.2628045
MLA
Wang P, et al.. "Early impact of lenvatinib on liver function and its prognostic significance: a single-center retrospective study.." Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, vol. 31, no. 2, 2026, pp. 132-140.
PMID
41652909 ↗
Abstract 한글 요약
[OBJECTIVE] Lenvatinib shows efficacy for tumor response and survival in patients with advanced hepatocellular carcinoma (HCC). We aim to assess the effect of lenvatinib on liver function.
[METHODS] This single-center retrospective cohort study included 40 patients with advanced HCC who received ≥ 2 months of lenvatinib treatment from January 2020 to January 2024 and had at least one efficacy and safety assessment.
[RESULTS] The ALBI score showed a slight but significant increase of 0.112 points, from -2.517 at baseline to -2.405 following 2-month of treatment (P < 0.05). With a median follow-up of 18.5 months, the median overall survival was 22.8 months (95% CI: 16.3-29.3), and the median progression-free survival was 12.7 months (95% CI: 9.1-16.3). Both COX regression and Kaplan-Meier analyses indicated that impaired baseline liver function was associated with adverse clinical outcomes. Additionally, treatment response emerged as an independent prognostic factor.
[CONCLUSIONS] The baseline ALBI score serves as a key prognostic marker, highlighting the necessity for meticulous monitoring of hepatic function, particularly in patients with compromised baseline liver reserve.
[LIMITATIONS] The limitations of this study include its retrospective design and the potential for selection bias arising from the requirement for at least 2 months of treatment.
[METHODS] This single-center retrospective cohort study included 40 patients with advanced HCC who received ≥ 2 months of lenvatinib treatment from January 2020 to January 2024 and had at least one efficacy and safety assessment.
[RESULTS] The ALBI score showed a slight but significant increase of 0.112 points, from -2.517 at baseline to -2.405 following 2-month of treatment (P < 0.05). With a median follow-up of 18.5 months, the median overall survival was 22.8 months (95% CI: 16.3-29.3), and the median progression-free survival was 12.7 months (95% CI: 9.1-16.3). Both COX regression and Kaplan-Meier analyses indicated that impaired baseline liver function was associated with adverse clinical outcomes. Additionally, treatment response emerged as an independent prognostic factor.
[CONCLUSIONS] The baseline ALBI score serves as a key prognostic marker, highlighting the necessity for meticulous monitoring of hepatic function, particularly in patients with compromised baseline liver reserve.
[LIMITATIONS] The limitations of this study include its retrospective design and the potential for selection bias arising from the requirement for at least 2 months of treatment.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Retrospective Studies
- Male
- Phenylurea Compounds
- Female
- Liver Neoplasms
- Quinolines
- Middle Aged
- Carcinoma
- Hepatocellular
- Aged
- Prognosis
- Liver
- Liver Function Tests
- Antineoplastic Agents
- Adult
- Kaplan-Meier Estimate
- Hepatocellular carcinoma
- albumin-bilirubin grade
- lenvatinib
- liver reserve function
같은 제1저자의 인용 많은 논문 (5)
- Application progress of tRNA modification in gynecological tumors: A review.
- Integrated analysis and functional validation reveal KCNQ1 tumor suppressor targeting by dahuang Zhechong Pills via cuproptosis modulation in colorectal cancer.
- siRNA Nanoparticle Delivery Strategies and Clinical Trial Advances in Tumor Therapy.
- Retraction notice to "A chitosan-camouflaged nanomedicine triggered by hierarchically stimuli to release drug for multimodal imaging-guided chemotherapy of breast cancer" [Carbohydrate Polymers 335 (2024) 122073].
- Succinylated D-Type Neuropeptide Integrated with Iron-Based Probes for Regulating Mitochondrial Function and Homeostasis in Breast Cancer.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.